Shattuck Labs
About
Overview
Mission & Vision
Management
Board of Directors
Advisory Board
Our Science
ARC Platform
GADLEN Platform
Posters
Publications
Pipeline
Clinical
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Discovery
Clinical Trials
Overview
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Careers
Intro to Shattuck
Values
Benefits
Join Our Team
News & Events
Contact
Locations
Contact Us
Our Science
Our Science
About
Overview
Mission & Vision
Management
Board of Directors
Advisory Board
Our Science
ARC Platform
GADLEN Platform
Posters
Publications
Pipeline
Clinical
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Discovery
Clinical Trials
Overview
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Careers
Intro to Shattuck
Values
Benefits
Join Our Team
News & Events
Contact
Locations
Contact Us
Publications
Year
All
2019
Cancer Immunology Research
December 20, 2019
CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity
Journal for ImmunoTherapy of Cancer
January 25, 2019
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Cancer Immunology Research
December 20, 2019
CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity
Journal for ImmunoTherapy of Cancer
January 25, 2019
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
About
Overview
Mission & Vision
Management
Board of Directors
Advisory Board
Our Science
ARC Platform
GADLEN Platform
Posters
Publications
Pipeline
Clinical
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Discovery
Clinical Trials
Overview
SL-172154
SIRPα-Fc-CD40L
SL-279252
PD1-Fc-OX40L
Careers
Intro to Shattuck
Values
Benefits
Join Our Team
News & Events
Contact
Locations
Contact Us
Follow Us
